TP53 and neoplasm: In vitro, both compounds exhibit single-agent efficacy in p53- and ATM-deficient tumor models, as well as sensitization to or synergy with gemcitabine, cisplatin, ionizing radiation, and PARP inhibition [46,47,136,137,138].